Aprepitant for Erlotinib-Induced Pruritus
- 22 July 2010
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 363 (4) , 397-398
Abstract
Aprepitant is the first commercially available drug of a new class of neurokinin-1–receptor antagonists for treating chemotherapy-induced nausea and vomiting. The dominant ligand for the neurokinin-1 receptor is substance P.1,2 An increase in the number of neurokinin-1 receptors on keratinocytes has been found in patients with chronic pruritus. A recent report described an improvement in pruritus related to the Sézary syndrome after aprepitant administration.3Keywords
This publication has 3 references indexed in Scilit:
- Aprepitant as an Antipruritic Agent?New England Journal of Medicine, 2009
- Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitantExpert Opinion on Drug Metabolism & Toxicology, 2009
- AprepitantDrugs, 2009